{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:56:19Z","timestamp":1790546179532,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e33263","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T19:47:58Z","timestamp":1718740078000},"page":"e33263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of immunotherapeutic strategies for first-episode Isolated Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Optic Neuritis: A single-centre retrospective study"],"prefix":"10.1016","volume":"10","author":[{"given":"Juan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqiu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuntao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2024.e33263_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.heliyon.2024.e33263_bib2","article-title":"Poor visual outcome after first attack in a cohort of patients with myelin oligodendrocyte glycoprotein-related optic neuritis","author":"Handzic","year":"2023","journal-title":"J. Neuro Ophthalmol."},{"key":"10.1016\/j.heliyon.2024.e33263_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brainres.2017.08.012","article-title":"Time is vision in recurrent optic neuritis","volume":"1673","author":"Osinga","year":"2017","journal-title":"Brain Res."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33263_bib4","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG Serostatus with relapse after acute disseminated encephalomyelitis and proposed Diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33263_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33263_bib6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00415-018-9160-9","article-title":"Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults","volume":"266","author":"Cobo-Calvo","year":"2019","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33263_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in Children with demyelinating Syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33263_bib8","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/WNO.0000000000001684","article-title":"The treatment of myelin oligodendrocyte glycoprotein antibody disease: a State-of-the-Art review","volume":"42","author":"Chwalisz","year":"2022","journal-title":"J. Neuro Ophthalmol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33263_bib9","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33263_bib10","article-title":"Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: data from a nationwide registry in Argentina","volume":"7","author":"Contentti","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33263_bib11","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","article-title":"Diagnosis and classification of optic neuritis","volume":"21","author":"Petzold","year":"2022","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33263_bib12","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.heliyon.2024.e33263_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104237","article-title":"Details and outcomes of a large cohort of MOG-IgG associated optic neuritis","volume":"68","author":"Chen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33263_bib14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/archopht.1995.01100020014004","article-title":"The optic neuritis treatment trial: three-year follow-up results","volume":"113","author":"Beck","year":"1995","journal-title":"Arch. Ophthalmol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33263_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and Aquaporin-4-IgG in patients in the optic neuritis treatment trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.heliyon.2024.e33263_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103222","article-title":"Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease","volume":"56","author":"Akaishi","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33263_bib17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jnnp-2022-330360","article-title":"Time to steroids impacts visual outcome of optic neuritis in MOGAD","volume":"94","author":"Rode","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33263_bib18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.exer.2008.05.017","article-title":"Inflammatory demyelination induces axonal injury and retinal ganglion cell apoptosis in experimental optic neuritis","volume":"87","author":"Shindler","year":"2008","journal-title":"Exp. Eye Res."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33263_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0006-8993(99)01191-9","article-title":"Axonal cytoskeleton changes in experimental optic neuritis","volume":"824","author":"Zhu","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.heliyon.2024.e33263_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105518","article-title":"Isolated myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in adults: the importance of age of onset and prognosis-related radiological features","volume":"85","author":"Zhao","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33263_bib21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol."},{"issue":"21","key":"10.1016\/j.heliyon.2024.e33263_bib22","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33263_bib23","article-title":"MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response","volume":"4","author":"Pandit","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33263_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e33263_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.679430","article-title":"The clinical, radiologic, and prognostic differences between pediatric and adult patients with myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33263_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.42780","article-title":"Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom","volume":"5","author":"Satukijchai","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e33263_bib27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/jnnp-2022-330901","article-title":"Clinical feature and disease outcome in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder: a Chinese study","volume":"94","author":"ZhangBao","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33263_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/jnnp-2022-330237","article-title":"Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study","volume":"94","author":"Gastaldi","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e33263_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.heliyon.2024.e33263_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2022.01.015","article-title":"Vision prognosis and associated factors of optic neuritis in dependence of glial autoimmune antibodies","volume":"239","author":"Yang","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.heliyon.2024.e33263_bib31","article-title":"Clinical features and imaging findings of myelin oligodendrocyte glycoprotein-IgG-associated disorder (MOGAD)","volume":"14","author":"Li","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33263_bib32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000705","article-title":"Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study","volume":"7","author":"Li","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33263_bib33","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1007\/s00415-020-10236-4","article-title":"Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis","volume":"268","author":"Lu","year":"2021","journal-title":"J. Neurol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024092946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024092946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:58:31Z","timestamp":1790542711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024092946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024092946"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33263","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing of immunotherapeutic strategies for first-episode Isolated Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Optic Neuritis: A single-centre retrospective study","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e33263"}}